MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s15010-025-02651-4

Медицинская библиотека · Infection · 2025

Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.

Ehrlich S, Eufinger J, Tahiri N, Jurinovic V, Mansournia S, Kunz W G, Jung J, Herold T, Subklewe M, Bücklein V, von Bergwelt-Baildon M, Spiekermann K

СтатьяПеревод в очереди

Аннотация

PURPOSE: Recent advances in the treatment of acute myeloid leukemia (AML) and optimized supportive care have improved survival outcomes. However, infections during remission induction chemotherapy remain a leading cause of morbidity and mortality. While antifungal prophylaxis is standard, the role of routine antibacterial prophylaxis is increasingly debated due to adverse effects and resistance. This study aimed to characterize infectious complications in a real-world AML cohort receiving induction chemotherapy without routine antibacterial prophylaxis.

METHODS

We retrospectively analyzed 103 adults with newly diagnosed AML who underwent intensive induction therapy at LMU University Hospital between January 2019 and December 2022. All patients received antifungal prophylaxis whereas antibacterial fluoroquinolone (FQ) prophylaxis was not administered. We assessed febrile episodes, clinically and microbiologically documented infections, ICU/IMC admissions, and 30-/90-day mortality.

RESULTS

Febrile episodes occurred in almost all patients. Clinically documented infections accounted for 29.8% and microbiologically confirmed infections for 22.9% of febrile events. Bacteraemia was evenly distributed between Gram-positive and Gram-negative pathogens; multidrug resistance was rare. Proven or probable invasive fungal infections occurred in 6.8% of patients. In 47.2% of cases, the cause of fever remained unknown. Infection-related 30-day mortality was 4.9%. Factors associated with increased 30-day mortality included age ≥ 65 years, ECOG ≥ 2, secondary AML, and ICU/IMC admission for infection.

CONCLUSION

Infections remain a major challenge during AML induction therapy. Our findings suggest that FQ prophylaxis should be reevaluated in this setting, focussing on a more individualized approach. In addition, novel diagnostic tools are urgently needed to enable earlier and more targeted infection management in this high-risk population.

Для цитирования: Ehrlich S, Eufinger J, Tahiri N, Jurinovic V, Mansournia S, Kunz W G, Jung J, Herold T, Subklewe M, Bücklein V, von Bergwelt-Baildon M, Spiekermann K. Infections during AML induction chemotherapy in a contemporary cohort without fluoroquinolone prophylaxis.. Infection. 2025. DOI: 10.1007/s15010-025-02651-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.